Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)

This post-marketing surveillance (PMS) study is designed to investigate the efficacy and safety of azathioprine tablets in Japanese subjects whom liver transplantation is performed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Diseases Digestive System Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who undergo liver transplantation and azathioprine tablet was administered

Exclusion criteria

As this is PMS study, there are no exclusion criteria but contraindications are as follows.

Subjects with hypersensitivity to the ingredients of azathioprine tablet
Subjects who is pregnant or might be pregnant
Subjects whose white count is lower than 3000/cubic millimeter

Treatment and study plan

azathioprine

Drug

Primary outcomes

The number of incidence of adverse events related to azathioprine tablets and serious adverse events

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start: 2002
Primary completion: 2011
Study completion: 2011
First posted: Jul 11, 2011
Registry last updated: Sep 3, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed